Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02867618 · ClinicalTrials.gov registry record · Phase 1
Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma
A Phase 1 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT02867618 is a Phase 1 study that was terminated before completion, run by Columbia University. The registered enrollment target is 14 participants.
The verdict
NCT02867618, a Phase 1 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is an open label, phase I/II, dose-escalation study in the initial phase I followed by a phase II. The primary objective of the phase I is to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of the combinations of TGR-1202 and carfilzomib in participants with relapsed and refractory (R/R) non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). The safety and toxicity of this combination will be evaluated throughout the entire study. If the combination of TGR-1202 and carfilzomib is found to be feasible and an MTD is established, the phase II part of the study will be initiated. Phase II will consist of a 2-stage design of the combination of TGR-1202 and carfilzomib for participants with R/R NHL.
Interventions
- DRUG Carfilzomib
- DRUG TGR-1202
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-10-16 |
| Est. Completion | 2020-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02867618
The ClinicalTrials.gov registry entry for NCT02867618 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carfilzomib is the first listed.
NCT02867618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02867618 about?
NCT02867618 is a clinical study titled "Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma". This is an open label, phase I/II, dose-escalation study in the initial phase I followed by a phase II. The primary objective of the phase I is to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of the combinations of TGR-1202 and carfilzomib in participants with relapse...
What is the current status of trial NCT02867618?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2016-10-16. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT02867618?
The interventions under investigation include: Carfilzomib (DRUG), TGR-1202 (DRUG).
Who is sponsoring clinical trial NCT02867618?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.